Which has better valuation & earnings, ABVX or NTRA?

Natera has higher revenue and earnings than Abivax. Natera is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Natera $2.31B 19.31 -$208.16M -$1.36 N/A

Is ABVX or NTRA more profitable?

Abivax has a net margin of 0.00% compared to Natera's net margin of -7.11%. Natera's return on equity of -11.82% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Natera -7.11% -11.82% -8.19%

Does the media refer more to ABVX or NTRA?

In the previous week, Natera had 28 more articles in the media than Abivax. MarketBeat recorded 30 mentions for Natera and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Natera's score of 0.74 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Natera 11 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Is RVMD or ABVX more profitable?

Revolution Medicines' return on equity of -88.20% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Revolution Medicines N/A -88.20% -57.85% Abivax N/A -99.02% -70.26%

Does the media refer more to RVMD or ABVX?

In the previous week, Revolution Medicines had 13 more articles in the media than Abivax. MarketBeat recorded 15 mentions for Revolution Medicines and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Revolution Medicines' score of 0.80 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 7 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has preferable earnings & valuation, BIIB or ABVX?

Biogen has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $10.03B 3.09 $1.29B $5.65 37.12 Abivax N/A N/A -$380.27M -$5.21 N/A

Is BIIB or ABVX more profitable?

Biogen has a net margin of 8.32% compared to Abivax's net margin of 0.00%. Biogen's return on equity of 11.18% beat Abivax's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% Abivax N/A -99.02% -70.26%

Does the media favor BIIB or ABVX?

In the previous week, Biogen had 7 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Biogen and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Biogen's score of 0.92 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 3 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to ALNY or ABVX?

In the previous week, Alnylam Pharmaceuticals had 11 more articles in the media than Abivax. MarketBeat recorded 13 mentions for Alnylam Pharmaceuticals and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Alnylam Pharmaceuticals' score of 0.26 indicating that Abivax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has higher valuation and earnings, ABVX or INSM?

Abivax has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Abivax N/A N/A -$380.27M -$5.21 N/A Insmed $606.42M 44.32 -$1.28B -$4.11 N/A

Is ABVX or INSM more profitable?

Abivax has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Abivax's return on equity of -99.02% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets Abivax N/A -99.02% -70.26% Insmed -76.94% -123.94% -44.30%

Does the media refer more to ABVX or INSM?

In the previous week, Insmed had 23 more articles in the media than Abivax. MarketBeat recorded 25 mentions for Insmed and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Insmed's score of 0.72 indicating that Abivax is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abivax 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Insmed 7 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Abivax (ABVX) Competitors

$118.86 -2.60 (-2.14%)

As of 11:44 AM Eastern

Compare

ABVX vs. NTRA, RVMD, BIIB, ALNY, and INSM

Should you buy Abivax stock or one of its competitors? Abivax's main competitors and comparable companies include Natera (NTRA), Revolution Medicines (RVMD), Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Abivax compare to Natera?

Abivax (NASDAQ:ABVX) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings.

In the previous week, Natera had 28 more articles in the media than Abivax. MarketBeat recorded 30 mentions for Natera and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Natera's score of 0.74 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Natera	11 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Abivax presently has a consensus price target of $156.50, indicating a potential upside of 30.38%. Natera has a consensus price target of $319.38, indicating a potential upside of 3.36%. Given Abivax's higher possible upside, research analysts plainly believe Abivax is more favorable than Natera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Natera	1 Sell rating(s)	4 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.82

47.9% of Abivax shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 5.1% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Natera has a beta of 1.51, meaning that its share price is 51% more volatile than the broader market.

Abivax has a net margin of 0.00% compared to Natera's net margin of -7.11%. Natera's return on equity of -11.82% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Natera	-7.11%	-11.82%	-8.19%

Natera has higher revenue and earnings than Abivax. Natera is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Natera	$2.31B	19.31	-$208.16M	-$1.36	N/A

Summary

Natera beats Abivax on 12 of the 16 factors compared between the two stocks.

How does Abivax compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and Abivax (NASDAQ:ABVX) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Revolution Medicines currently has a consensus price target of $161.79, suggesting a potential downside of 19.74%. Abivax has a consensus price target of $156.50, suggesting a potential upside of 30.38%. Given Abivax's higher probable upside, analysts clearly believe Abivax is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.91
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Revolution Medicines has a beta of 1.39, indicating that its stock price is 39% more volatile than the broader market. Comparatively, Abivax has a beta of 1.03, indicating that its stock price is 3% more volatile than the broader market.

Revolution Medicines' return on equity of -88.20% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-88.20%	-57.85%
Abivax	N/A	-99.02%	-70.26%

Abivax has lower revenue, but higher earnings than Revolution Medicines. Abivax is trading at a lower price-to-earnings ratio than Revolution Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	3,731.11	-$1.13B	-$8.82	N/A
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

94.3% of Revolution Medicines shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Revolution Medicines had 13 more articles in the media than Abivax. MarketBeat recorded 15 mentions for Revolution Medicines and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Revolution Medicines' score of 0.80 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	7 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Summary

Revolution Medicines beats Abivax on 11 of the 15 factors compared between the two stocks.

How does Abivax compare to Biogen?

Biogen (NASDAQ:BIIB) and Abivax (NASDAQ:ABVX) are both large-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.

87.9% of Biogen shares are held by institutional investors. Comparatively, 47.9% of Abivax shares are held by institutional investors. 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biogen has a net margin of 8.32% compared to Abivax's net margin of 0.00%. Biogen's return on equity of 11.18% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
Abivax	N/A	-99.02%	-70.26%

Biogen has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$10.03B	3.09	$1.29B	$5.65	37.12
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

In the previous week, Biogen had 7 more articles in the media than Abivax. MarketBeat recorded 9 mentions for Biogen and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Biogen's score of 0.92 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	3 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Biogen has a beta of 0.17, suggesting that its stock price is 83% less volatile than the broader market. Comparatively, Abivax has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Biogen currently has a consensus target price of $227.07, suggesting a potential upside of 8.28%. Abivax has a consensus target price of $156.50, suggesting a potential upside of 30.38%. Given Abivax's stronger consensus rating and higher probable upside, analysts clearly believe Abivax is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Biogen beats Abivax on 12 of the 16 factors compared between the two stocks.

How does Abivax compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Abivax (NASDAQ:ABVX) are both large-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Alnylam Pharmaceuticals had 11 more articles in the media than Abivax. MarketBeat recorded 13 mentions for Alnylam Pharmaceuticals and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Alnylam Pharmaceuticals' score of 0.26 indicating that Abivax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Alnylam Pharmaceuticals currently has a consensus target price of $393.86, indicating a potential upside of 75.72%. Abivax has a consensus target price of $156.50, indicating a potential upside of 30.38%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe Alnylam Pharmaceuticals is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Alnylam Pharmaceuticals has a beta of 0.3, suggesting that its share price is 70% less volatile than the broader market. Comparatively, Abivax has a beta of 1.03, suggesting that its share price is 3% more volatile than the broader market.

Alnylam Pharmaceuticals has higher revenue and earnings than Abivax. Abivax is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$4.80B	6.24	$313.75M	$5.38	41.66
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Abivax's net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Abivax's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Abivax	N/A	-99.02%	-70.26%

Summary

Alnylam Pharmaceuticals beats Abivax on 14 of the 16 factors compared between the two stocks.

How does Abivax compare to Insmed?

Abivax (NASDAQ:ABVX) and Insmed (NASDAQ:INSM) are both large-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

47.9% of Abivax shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Abivax has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Abivax's return on equity of -99.02% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Abivax	N/A	-99.02%	-70.26%
Insmed	-76.94%	-123.94%	-44.30%

Abivax has a beta of 1.03, meaning that its share price is 3% more volatile than the broader market. Comparatively, Insmed has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

Abivax presently has a consensus price target of $156.50, indicating a potential upside of 30.38%. Insmed has a consensus price target of $205.52, indicating a potential upside of 66.98%. Given Insmed's stronger consensus rating and higher probable upside, analysts clearly believe Insmed is more favorable than Abivax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Abivax	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	2 Strong Buy rating(s)	3.00

Abivax has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than Abivax, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Abivax	N/A	N/A	-$380.27M	-$5.21	N/A
Insmed	$606.42M	44.32	-$1.28B	-$4.11	N/A

In the previous week, Insmed had 23 more articles in the media than Abivax. MarketBeat recorded 25 mentions for Insmed and 2 mentions for Abivax. Abivax's average media sentiment score of 1.85 beat Insmed's score of 0.72 indicating that Abivax is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Abivax	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Insmed	7 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Insmed beats Abivax on 9 of the 16 factors compared between the two stocks.

Get Abivax News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ABVX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ABVX vs. The Competition

Export

Metric	Abivax	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$10.45B	$3.69B	$6.97B	$13.06B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-22.99	10.36	269.56	25.27
Price / Sales	N/A	1,288.04	596.64	100.41
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	18.27	17.39	13.00	6.30
Net Income	-$380.27M	-$13.32M	$3.45B	$347.83M
7 Day Performance	-8.33%	0.34%	0.57%	0.94%
1 Month Performance	-11.03%	0.13%	1.22%	0.90%
1 Year Performance	72.56%	53.78%	66.67%	20.40%

Abivax Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ABVX Abivax	2.4906 of 5 stars	$118.86 -2.1%	$156.50 +31.7%	+73.9%	$10.37B	N/A	N/A	61	Positive News
NTRA Natera	2.667 of 5 stars	$316.24 +19.2%	$273.11 -13.6%	+97.1%	$45.17B	$2.50B	N/A	6,140	Analyst Forecast
RVMD Revolution Medicines	2.4202 of 5 stars	$197.69 -0.1%	$153.05 -22.6%	+460.4%	$41.98B	$11.58M	N/A	250	Analyst Forecast
BIIB Biogen	4.0463 of 5 stars	$206.60 +0.2%	$224.61 +8.7%	+55.8%	$30.51B	$9.89B	36.55	7,500	Analyst Downgrade
ALNY Alnylam Pharmaceuticals	4.8288 of 5 stars	$215.60 -0.2%	$396.72 +84.0%	-47.5%	$28.80B	$3.71B	40.01	2,770

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ABVX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Abivax (ABVX) Competitors